OM (Outset Medical, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by OM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2026-08-18 | Renee Gaeta | Chief Financial Officer | Sell | — | — |
| 2026-08-18 | John L. Brottem | General Counsel | Sell | — | — |
| 2026-06-29 | Renee Gaeta | Chief Financial Officer | A | — | — |
| 2026-06-29 | John L. Brottem | General Counsel | A | — | — |
| 2026-06-29 | Leslie Trigg | Chair and CEO | A | — | — |
| 2026-06-05 | KEVIN C OBOYLE | Director | A | — | — |
| 2026-06-05 | Karen Prange | Director | A | — | — |
| 2026-06-05 | Renee Gaeta | Chief Financial Officer | Sell | — | — |
| 2026-06-05 | D KEITH GROSSMAN | Director | A | — | — |
| 2026-06-05 | BRENT D. LANG | Director | A | — | — |
| 2026-06-05 | PATRICK T HACKETT | Director | A | — | — |
| 2026-06-05 | Karen Drexler | Director | A | — | — |
| 2026-05-19 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2026-05-19 | Marc Nash | EVP Operations R&D & Service | Sell | — | — |
| 2026-05-19 | John L. Brottem | General Counsel | Sell | — | — |
| 2026-05-18 | Braden Michael Leonard | 10%+ Owner | X | — | — |
| 2026-05-12 | Braden Michael Leonard | 10%+ Owner | X | — | — |
| 2026-04-08 | Derick A. Elliott | EVP, Commercial | A | — | — |
| 2026-02-19 | Marc Nash | EVP Operations R&D & Service | Sell | — | — |
| 2026-02-19 | John L. Brottem | General Counsel | Sell | — | — |
| 2026-02-19 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2026-01-21 | John L. Brottem | General Counsel | Sell | — | — |
| 2026-01-21 | Marc Nash | EVP Operations R&D & Service | Sell | — | — |
| 2026-01-21 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2026-01-12 | Karen Prange | Director | A | — | — |
| 2026-01-08 | John L. Brottem | General Counsel | Sell | — | — |
| 2026-01-08 | Marc Nash | EVP Operations R&D & Service | Sell | — | — |
| 2026-01-08 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2025-12-02 | Karen Drexler | Director | Sell | — | — |
| 2025-11-18 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2025-11-18 | Marc Nash | EVP Operations R&D & Service | Sell | — | — |
| 2025-11-18 | John L. Brottem | General Counsel | Sell | — | — |
| 2025-08-25 | Marc Nash | EVP, R&D, Operations and Serv. | A | — | — |
| 2025-08-18 | Marc Nash | SVP Operations and R&D | Sell | — | — |
| 2025-08-18 | John L. Brottem | General Counsel | Sell | — | — |
| 2025-08-18 | Leslie Trigg | Chair and CEO | Sell | — | — |
| 2025-06-11 | John L. Brottem | General Counsel | A | — | — |
| 2025-06-11 | Marc Nash | SVP Operations and R&D | A | — | — |
| 2025-06-11 | Renee Gaeta | Chief Financial Officer | A | — | — |
| 2025-06-11 | Leslie Trigg | Chair and CEO | A | — | — |
| 2025-06-04 | D KEITH GROSSMAN | Director | A | — | — |
| 2025-06-04 | Andrea Lynn Saia | Director | A | — | — |
| 2025-06-04 | KEVIN C OBOYLE | Director | A | — | — |
| 2025-06-04 | Karen Drexler | Director | A | — | — |
| 2025-06-04 | PATRICK T HACKETT | Director | A | — | — |
| 2025-06-04 | BRENT D. LANG | Director | A | — | — |
| 2025-05-16 | John L. Brottem | General Counsel | Sell | — | — |
| 2025-05-16 | Marc Nash | SVP Operations and R&D | Sell | — | — |
| 2025-05-16 | Nabeel Ahmed | Chief Financial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,519,701 | — |
| — | Director | 579,550 | — |
| — | Director | 305,700 | — |
| — | Chair and CEO | 195,181 | — |
| — | Director | 189,172 | — |
| — | Chief Financial Officer | 180,840 | — |
| — | EVP, Commercial | 96,000 | — |
| — | General Counsel | 87,475 | — |
| — | Director | 54,360 | — |
| — | Director | 45,184 | — |
| — | EVP Operations R&D & Service | 38,393 | — |
| — | Director | 37,430 | — |
| — | Director | 34,785 | — |
| — | Director | 29,334 | — |
| — | Director | 23,400 | — |
| — | Chief Commercial Officer | 21,356 | — |
| — | Chief Technology Officer | 17,688 | — |
| — | Chief Financial Officer | 16,096 | — |
| — | Director | 12,175 | — |
| — | Chief Operating Officer | 6,962 | — |
| — | Director | 5,357 | — |
| — | Chief People Officer | 4,097 | — |
| — | Director | 3,061 | — |
| — | Director | 1,739 | — |
| — | Director | 1,640 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OM quote page; the site-wide leaderboard is on the insider transactions hub.